Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

丹诺医药
TENNOR THERAPEUTICS

TenNor Therapeutics (Suzhou) Limited
丹諾醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6872)

VOLUNTARY ANNOUNCEMENT ENTERING INTO THE SUPPLEMENTAL AGREEMENT TO THE EXCLUSIVE COMMERCIALIZATION COLLABORATION AGREEMENT WITH GRAND LIFE SCIENCE

This announcement is made by TenNor Therapeutics (Suzhou) Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business developments of the Group.

BACKGROUND

Reference is made to the prospectus of the Company dated May 14, 2026 (the "**Prospectus**"), which sets out, among other things, the collaboration between the Company and a subsidiary of Grand Life Sciences Group Limited (together with Grand Life Sciences Group Limited, "**Grand Life Science**") for the commercialization of rifasutenizol (TNP-2198). Unless the context requires otherwise, terms used in this announcement shall have the same meanings as those defined in the Prospectus.

As disclosed in the Prospectus, the Company entered into an exclusive commercialization collaboration agreement (the "**Collaboration Agreement**") with Grand Life Science in November 2024 for the commercialization of rifasutenizol in Greater China (excluding Taiwan), and made amendments to the Collaboration Agreement in January 2026. Through commercialization collaboration with Grand Life Science, the Company aims to leverage Grand Life Science's strong marketing capabilities and extensive commercialization resources in gastrointestinal disease management to facilitate a quick uptake and broad patient access, driving the successful marketing of rifasutenizol.

Pursuant to the Collaboration Agreement, Grand Life Science has the exclusive right to carry out commercialization activities throughout the marketing, promotion and distribution of rifasutenizol within the Authorized Territory and Authorized Scope. The Collaboration Agreement also contains certain milestone and termination arrangements, including that if the Company is unable to receive the marketing approval for the first indication of rifasutenizol in China before December 31, 2026, Grand Life Science may unilaterally terminate the Collaboration Agreement by written notice.

ENTERING INTO THE SUPPLEMENTAL AGREEMENT TO THE COLLABORATION AGREEMENT

The Company has been actively advancing the consideration and approval process for obtaining the marketing approval for the first indication of rifasutenizol in China and the related preparations for commercialization. In order to align with the relevant review process, ensure that the collaboration arrangements remain consistent with the anticipated commercialization timeline of rifasutenizol, and further strengthen the long-term collaboration between the Company and Grand Life Science, the Board is pleased to announce that, on November 12, 2026, the Company entered into a supplemental agreement to the Collaboration Agreement (the "**Supplemental Agreement to the Collaboration Agreement**") with Grand Life Science, pursuant to which, the parties agreed to extend, from December 31, 2026 to July 31, 2027, the relevant deadline under the Collaboration Agreement relating to Grand Life Science's right to unilaterally terminate the Collaboration Agreement by written notice if the Company fails to receive the marketing approval for the first indication of rifasutenizol in China before the specified date.

Save for the relevant adjustments to the long stop date under the Supplemental Agreement to the Collaboration Agreement, there are no other substantial changes to the other terms of the Collaboration Agreement, which shall remain in full force and effect.

REASONS FOR AND BENEFITS OF ENTERING INTO THE SUPPLEMENTAL AGREEMENT TO THE COLLABORATION AGREEMENT

The Board considers that the entering into of the Supplemental Agreement to the Collaboration Agreement will facilitate the alignment of the term of collaboration and the relevant termination arrangements under the Collaboration Agreement with the progress of obtaining marketing approval in China and commercialization of rifasutenizol, further safeguard the cooperative relationship established between the Company and Grand Life Science based on the Collaboration Agreement, and is in the interests of the Company and its shareholders as a whole.

ABOUT RIFASUTENIZOL (TNP-2198)

Rifasutenizol is the world's first new molecular entity ("**NME**") drug candidate developed to target *Helicobacter pylori* infection since the discovery of this pathogen in 1982. It features a unique dual-target synergistic mechanism of action: through a synergistic effect of inhibiting bacterial RNA polymerase to block the transcription process and generating free radicals through activation by nitroreductase to damage bacterial DNA and other components, it significantly enhances bactericidal efficacy, overcomes drug resistance, and substantially reduces the risk of resistance development.

The Company has completed seven clinical trials for rifasutenizol in China, including two Phase I clinical trials, two clinical pharmacology trials, two Phase II clinical trials and one Phase III clinical trial. Early-phase clinical data on rifasutenizol were published in The Lancet Infectious Diseases in 2024 as one of the featured articles, attracting global attention. The results of the Phase III clinical trial of rifasutenizol were also published in The Lancet Infectious Diseases on September 11, 2025. In addition, the Company presented the latest research findings on rifasutenizol at the 2025 Digestive Disease Week conference in the U.S., which is the world's largest international conference in the field of gastrointestinal diseases, and the presentation was selected as a Distinguished Plenary Presentation.

Recognizing its potential in treating *Helicobacter pylori* infection that may lead to severe and life-threatening conditions, the United States Food and Drug Administration has granted rifasutenizol the Qualified Infectious Disease Product designation.

The Company submitted drug marketing registration applications for rifasutenizol capsules to the National Medical Products Administration of the PRC (the "**NMPA**") in August 2025, and received a supplementary information notice issued by the Center for Drug Evaluation of the NMPA in June 2026. As of the date of this announcement, the submission of all supplementary information in respect of rifasutenizol has been completed.

ABOUT THE COMPANY

The Company is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated innovative therapies to address unmet clinical needs in disease areas associated with bacterial infections and bacterial metabolism. Relying on its proprietary multi-targeting conjugate molecule technology platform, the Company aims to deliver therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes.

As of the date of this announcement, the Company has established a drug research and development pipeline comprising eight innovative programs, including two core products, namely: rifasutenizol (TNP-2198), a multi-targeting conjugated NME candidate for the treatment of *Helicobacter pylori* infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and *Clostridioides difficile* infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infections and implant-associated bacterial infections (such as prosthetic joint infections, left ventricular assist device infections and catheter-related bloodstream infections).

We may not be able to ultimately market rifasutenizol for the treatment of *Helicobacter pylori* infection, and develop and market rifasutenizol for the treatment of bacterial vaginosis and *Clostridioides difficile* infection successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, November 13, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as an executive Director; (ii) Dr. Song Gaoguang as a non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as independent non-executive Directors.